EuBiologics Co. Ltd.
EuBiologics Co., Ltd., a biopharmaceutical company, focuses on developing vaccines against global pandemic and bacterial vaccines primarily in South Korea. It offers inactivated oral cholera vaccine under the Euvichol, Euvichol-Plus, and Euvichol-S names; and EuCorVac-19, a recombinant protein vaccine. The company also provides EcML that is used as a vaccine adjuvant, directly activating antigen … Read more
EuBiologics Co. Ltd. (206650) - Total Liabilities
Latest total liabilities as of September 2025: ₩58.92 Billion KRW
Based on the latest financial reports, EuBiologics Co. Ltd. (206650) has total liabilities worth ₩58.92 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
EuBiologics Co. Ltd. - Total Liabilities Trend (2021–2024)
This chart illustrates how EuBiologics Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
EuBiologics Co. Ltd. Competitors by Total Liabilities
The table below lists competitors of EuBiologics Co. Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hengong Precision Equipment Co Ltd
SHE:301261
|
China | CN¥1.19 Billion |
|
Hg Technologies Co Ltd
SHE:300847
|
China | CN¥139.16 Million |
|
Schweizerische Nationalbank
PINK:SWZNF
|
USA | $727.18 Billion |
|
Alma Media Oyj
HE:ALMA
|
Finland | €271.90 Million |
|
Harworth Group plc
PINK:HWGLF
|
USA | $358.73 Million |
|
AES Brasil Energia S.A
SA:AESB3
|
Brazil | R$14.99 Billion |
|
Clearpoint Neuro Inc
NASDAQ:CLPT
|
USA | $44.48 Million |
|
Continental Holdings Corp
TW:3703
|
Taiwan | NT$67.03 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down EuBiologics Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how EuBiologics Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for EuBiologics Co. Ltd. (2021–2024)
The table below shows the annual total liabilities of EuBiologics Co. Ltd. from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-09-30 | ₩70.05 Billion | +73.26% |
| 2023-09-30 | ₩40.43 Billion | -5.16% |
| 2022-09-30 | ₩42.63 Billion | +40.05% |
| 2021-09-30 | ₩30.44 Billion | -- |